Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up.
Clin Exp Dermatol 2016;
41:852-857. [PMID:
27753139 DOI:
10.1111/ced.12933]
[Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND
Limited data exist on the use of systemic antibiotic treatment for hidradenitis supportive (HS).
AIM
To investigate the effectiveness, safety and relapse rate of HS treated with a combination of daily oral clindamycin and rifampicin.
METHODS
This was a prospective, hospital-based study of oral clindamycin 600 mg and rifampicin 600 mg daily for 12 weeks for treatment of HS. Patients were followed up for 1 year to monitor for relapse.
RESULTS
In total, 26 patients with HS received oral clindamycin and rifampicin. Most were overweight or obese (73%), and most were smokers (88%). After 12 weeks, clinical response was noted in 19 patients (73%). Response was associated only with female sex (P = 0.02), and not with body mass index, Hurley stage or lesion location. Eight patients (31%) experienced adverse events. At the 1-year follow-up, there was sustained efficacy in 7 (41%) patients, while 10 (59%) had disease relapse after a mean time of 4.2 months.
CONCLUSIONS
Oral clindamycin with oral rifampicin for 12 weeks is an effective and tolerable regimen for HS.
Collapse